乐普医疗：MWN105注射液Ⅱ期临床试验完成首例受试者给药

Core Viewpoint - Lepu Medical (300003) announced that its subsidiary, Shanghai Minwei Biotechnology Co., Ltd., has initiated a Phase II clinical trial for its innovative drug MWN105 injection, aimed at treating overweight or obesity, with the first subject successfully dosed recently [1] Group 1 - The innovative drug MWN105 is being developed for the treatment of overweight or obesity [1] - The Phase II clinical trial has recently commenced with the successful dosing of the first participant [1]